Filing Details
- Accession Number:
- 0001395064-20-000084
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-05 09:52:38
- Reporting Period:
- 2020-06-03
- Accepted Time:
- 2020-06-05 09:52:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1693415 | Translate Bio Inc. | TBIO | Pharmaceutical Preparations (2834) | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1395064 | Takeda Pharmaceutical Co Ltd | 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo M0 103-8668 | No | No | Yes | No | |
| 1745009 | Shire Human Genetic Therapies, Inc. | 300 Shire Way Lexington MA 02421 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-06-03 | 40,086 | $19.75 | 6,824,992 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Weighted average of sales prices. Actual prices range from $19.11 to $20.00. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
- This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
- These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.
Billionaire Hedge Funds
